A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Pfizer

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: PF-05180999; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01429740

B3441001

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.

Enrollment: 29 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

male or female of non-childbearing potential,

Exclusion criteria

Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

29 participants in 2 patient groups, including a placebo group

PF-05180999

Experimental group

Treatment:

Drug: PF-05180999

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo